JP2014524735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524735A5 JP2014524735A5 JP2014514846A JP2014514846A JP2014524735A5 JP 2014524735 A5 JP2014524735 A5 JP 2014524735A5 JP 2014514846 A JP2014514846 A JP 2014514846A JP 2014514846 A JP2014514846 A JP 2014514846A JP 2014524735 A5 JP2014524735 A5 JP 2014524735A5
- Authority
- JP
- Japan
- Prior art keywords
- complement
- group
- diagnostic test
- snps
- companion diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000295 complement effect Effects 0.000 claims description 46
- 239000000090 biomarker Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 26
- 238000002405 diagnostic procedure Methods 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 238000002493 microarray Methods 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 6
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 6
- 230000008236 biological pathway Effects 0.000 claims description 6
- 239000003596 drug target Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 102100038495 Bile acid receptor Human genes 0.000 claims description 4
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 238000005251 capillar electrophoresis Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000840 electrochemical analysis Methods 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 102000004311 liver X receptors Human genes 0.000 claims description 4
- 108090000865 liver X receptors Proteins 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 4
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 4
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 3
- 108010085238 Actins Proteins 0.000 claims description 3
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 claims description 3
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 230000030648 nucleus localization Effects 0.000 claims description 3
- 230000009103 reabsorption Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000017144 Metabolic Skin disease Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical group CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 229960002938 bexarotene Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 210000004292 cytoskeleton Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000011285 therapeutic regimen Methods 0.000 claims description 2
- 101000613350 Homo sapiens Polycomb group RING finger protein 5 Proteins 0.000 description 1
- 102100040916 Polycomb group RING finger protein 5 Human genes 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494773P | 2011-06-08 | 2011-06-08 | |
| US61/494,773 | 2011-06-08 | ||
| PCT/US2012/041379 WO2012170704A2 (en) | 2011-06-08 | 2012-06-07 | Methods and compositions of predicting activity of retinoid x receptor modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524735A JP2014524735A (ja) | 2014-09-25 |
| JP2014524735A5 true JP2014524735A5 (enExample) | 2015-07-23 |
Family
ID=47296742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514846A Pending JP2014524735A (ja) | 2011-06-08 | 2012-06-07 | レチノイドｘレセプターの調節因子の活性を予測する方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10202652B2 (enExample) |
| EP (1) | EP2718486A4 (enExample) |
| JP (1) | JP2014524735A (enExample) |
| KR (1) | KR20140039278A (enExample) |
| CN (1) | CN103649386B (enExample) |
| AU (1) | AU2012267877B2 (enExample) |
| BR (1) | BR112013031221A2 (enExample) |
| CA (1) | CA2838207A1 (enExample) |
| MX (1) | MX2013014437A (enExample) |
| RU (1) | RU2013158861A (enExample) |
| SG (1) | SG195191A1 (enExample) |
| WO (1) | WO2012170704A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US11089959B2 (en) * | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) * | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| WO2015073896A2 (en) * | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN104131102B (zh) * | 2014-08-07 | 2016-06-15 | 马飞 | 一种判断nsclc患者对吉非替尼治疗反应性的试剂盒 |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| WO2016073855A1 (en) * | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| JOP20190025A1 (ar) * | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| WO2019044852A1 (ja) * | 2017-08-31 | 2019-03-07 | 株式会社資生堂 | レチノイドの副作用に対する感受性の決定方法 |
| CN108504733A (zh) * | 2017-11-29 | 2018-09-07 | 中山拓普基因科技有限公司 | 肿瘤个体化化疗用药指导基因snp位点检测组合物 |
| KR102169699B1 (ko) * | 2019-12-27 | 2020-10-23 | 주식회사 클리노믹스 | 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법 |
| IL296168A (en) | 2020-03-06 | 2022-11-01 | Denovo Biopharma Llc | Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters |
| KR20250118433A (ko) * | 2024-01-30 | 2025-08-06 | 서울대학교산학협력단 | 알츠하이머병 발병 위험도 예측을 위한 레이 복잡도 복사 점수 저하와 관련이 있는 단일염기다형성 마커 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1937244T3 (en) * | 2005-09-30 | 2018-10-29 | Io Therapeutics Llc | : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS |
| JP2009509539A (ja) | 2005-09-30 | 2009-03-12 | パーレジェン サイエンシーズ， インコーポレイテッド | 血糖調節の障害のスクリーニングおよび処置のための方法および組成物 |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2009134774A1 (en) | 2008-04-28 | 2009-11-05 | Expression Analysis | Methods and systems for simultaneous allelic contrast and copy number association in genome-wide association studies |
| US20120115912A1 (en) | 2009-07-10 | 2012-05-10 | Landreth Gary E | Rxr agonist compounds and methods |
| WO2011056688A2 (en) * | 2009-10-27 | 2011-05-12 | Caris Life Sciences, Inc. | Molecular profiling for personalized medicine |
| US7790396B1 (en) | 2009-12-23 | 2010-09-07 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
-
2012
- 2012-06-07 EP EP12797326.1A patent/EP2718486A4/en not_active Ceased
- 2012-06-07 SG SG2013087861A patent/SG195191A1/en unknown
- 2012-06-07 WO PCT/US2012/041379 patent/WO2012170704A2/en not_active Ceased
- 2012-06-07 KR KR1020147000545A patent/KR20140039278A/ko not_active Withdrawn
- 2012-06-07 CN CN201280027212.8A patent/CN103649386B/zh not_active Expired - Fee Related
- 2012-06-07 MX MX2013014437A patent/MX2013014437A/es not_active Application Discontinuation
- 2012-06-07 BR BR112013031221A patent/BR112013031221A2/pt not_active IP Right Cessation
- 2012-06-07 JP JP2014514846A patent/JP2014524735A/ja active Pending
- 2012-06-07 RU RU2013158861/10A patent/RU2013158861A/ru not_active Application Discontinuation
- 2012-06-07 US US14/124,668 patent/US10202652B2/en active Active
- 2012-06-07 AU AU2012267877A patent/AU2012267877B2/en not_active Ceased
- 2012-06-07 CA CA2838207A patent/CA2838207A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524735A5 (enExample) | ||
| Corces et al. | Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer’s and Parkinson’s diseases | |
| RU2013158861A (ru) | Способы и композиции для предсказания активности модулятора ретиноидного х-рецептора | |
| Hannum et al. | Genome-wide methylation profiles reveal quantitative views of human aging rates | |
| Heyn et al. | Distinct DNA methylomes of newborns and centenarians | |
| Okosun et al. | Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma | |
| Pedersen et al. | Genome-wide nucleosome map and cytosine methylation levels of an ancient human genome | |
| Lin et al. | Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing | |
| JP2022511765A (ja) | 祖先特異的な遺伝リスクスコア | |
| Kim et al. | Allelic imbalance sequencing reveals that single-nucleotide polymorphisms frequently alter microRNA-directed repression | |
| Fawzy et al. | Association of MIR-499a expression and seed region variant (rs3746444) with cardiovascular disease in Egyptian patients | |
| Faita et al. | Next generation sequencing in cardiovascular diseases | |
| Zhao et al. | Replicated associations of FADS1, MAD1L1, and a rare variant at 10q26. 13 with bipolar disorder in Chinese population | |
| Visconti et al. | Epigenetics of myotonic dystrophies: a minireview | |
| Bagheri et al. | Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3'-untranslated region of ErbB4 in breast cancer | |
| Yuan et al. | Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk | |
| White et al. | The population genomics of trans-specific inversion polymorphisms in Anopheles gambiae | |
| Niu et al. | Synergistic effects of gene polymorphisms of the renin–angiotensin–aldosterone system on essential hypertension in Kazakhs in Xinjiang | |
| Srivastava et al. | Single nucleotide polymorphisms of microRNA in cardiovascular diseases | |
| US20220073986A1 (en) | Method of characterizing a neurodegenerative pathology | |
| Koeken et al. | Resolving trained immunity with systems biology | |
| Van Rensburg et al. | Transcriptomics: the key to biomarker discovery during tuberculosis? | |
| Zhang et al. | Effects of genetic variations within goat PITX2 gene on growth traits and mRNA expression | |
| Wang et al. | The CMYA5 gene confers risk for both schizophrenia and major depressive disorder in the Han Chinese population | |
| Giri et al. | Genetic association of nuclear factor of activated T cells’3′ UTR and structural polymorphisms with susceptibility to generalized vitiligo in Gujarat population |